Is Incyte a public company?
Andrew Walker
Updated on February 07, 2026
Is Incyte a public company?
Incyte Corp is an American multinational pharmaceutical company based in Wilmington, Delaware….Incyte.
| Type | Public |
|---|---|
| Total assets | $US 3.56 billion (2020) |
| Total equity | $US 2.611 billion (2020) |
| Number of employees | 1600+ (2020) |
| Website |
How is market capitalization calculated?
Commonly referred to as “market cap,” it is calculated by multiplying the total number of a company’s outstanding shares by the current market price of one share. As an example, a company with 10 million shares selling for $100 each would have a market cap of $1 billion.
Is Incyte a good company?
Incyte is ranked #52 on the Best Pharmaceutical Companies to Work For in America list. Zippia’s Best Places to Work lists provide unbiased, data-based evaluations of companies. Rankings are based on government and proprietary data on salaries, company financial health, and employee diversity.
Is Incyte a good company to work for?
Incyte Workplace: excellent benefits & pays very well but culture is demotivating. Scientists & medicinal chemists are key to the future of this company. Lean organizational chart that lends itself to increased responsibility but not leadership or career progression opportunities for development.
Show less
Incyte (INCY) announces positive data from phase III studies on ruxolitinib cream for the treatment of vitiligo.
What is the current stock price of Incy?
Price Action: INCY shares are up 0.41% at $82.96 during the market session on the last check Monday. See more from BenzingaClick here for options trades from BenzingaIncyte’s Q1 Jakafi Sales Hit By Pandemic; Reaffirms 2021 Guidance© 2021 Benzinga.com. Benzinga does not provide investment advice.
What did Incyte do in the first quarter?
Incyte (INCY) beats earnings estimates in the first quarter but misses sales figure as Jakafi sales were weaker than expected.
When does Incyte’s Iclusig Phase 2 data come out?
Positive Analysis from Phase 2 OPTIC Study of Ponatinib (Iclusig) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) to be Presented at ASCO 2021 Data from Incyte’s Oncology Portfolio Accepted for Presentation at the 2021 ASCO Annual Meeting
What is the stock price of Incyte Corporation?
Incyte (INCY) announces positive data from phase III studies on ruxolitinib cream for the treatment of vitiligo.
Price Action: INCY shares are up 0.41% at $82.96 during the market session on the last check Monday. See more from BenzingaClick here for options trades from BenzingaIncyte’s Q1 Jakafi Sales Hit By Pandemic; Reaffirms 2021 Guidance© 2021 Benzinga.com. Benzinga does not provide investment advice.
Incyte (INCY) beats earnings estimates in the first quarter but misses sales figure as Jakafi sales were weaker than expected.
Positive Analysis from Phase 2 OPTIC Study of Ponatinib (Iclusig) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) to be Presented at ASCO 2021 Data from Incyte’s Oncology Portfolio Accepted for Presentation at the 2021 ASCO Annual Meeting
